EP300 and diffuse large B-cell lymphoma: In addition, in DLBCL, pan BET/CBP/EP300 inhibitor (NEO2734) was found to be more effective than BETi or CBP/EP300 inhibitors alone, and the addition of venetoclax alleviated the resistance to NEO2734 [89].